INVITRO SUSCEPTIBILITY ANALYSIS OF Uvarium chamae EXTRACT ON ECZEMA INFECTION

Abstract

Eczema, a common dermatological condition, often presents with inflammation and skin irritation, frequently complicated by secondary fungal infections. Traditional treatments, such as topical corticosteroids and antifungal agents, have limitations, including adverse effects and antimicrobial resistance. This study investigated the in vitro antifungal activity of Uvarium chamae extracts against common fungal pathogens associated with eczema, including Candida spp., Aspergillus spp., Malassezia species, and Trichophyton spp., with the aim of evaluating its potential as an alternative therapeutic option. Ethanolic and aqueous extracts of Uvarium chamae were prepared and tested for antifungal activity using the disc diffusion method. The zone of inhibition was measured at various concentrations (1, 2, 4, and 8 mg/mL), and the minimum inhibitory concentration (MIC) was determined. Comparative analysis was also conducted with fluconazole as a standard antifungal agent. The ethanolic extract showed significant antifungal activity, with larger zones of inhibition compared to the aqueous extract, particularly against Candida spp. and Aspergillus spp., with maximum inhibition at 8 mg/mL. The aqueous extract exhibited weaker activity, with smaller inhibition zones for all tested fungi. The results suggest that Uvarium chamae has promising antifungal properties, with the ethanolic extract being more effective than the aqueous one. In conclusion, Uvarium chamae demonstrates potential as a natural antifungal agent against common pathogens involved in eczema infections. Further clinical studies are needed to explore its therapeutic efficacy and safety for treating eczema-related fungal infections.